Exploring the Impact of de Novo Everolimus on Key Determinants of Long Term Outcome After Kidney Transplantation: NODAT, Viral Infection, DSA, Proteinuria and Graft Histology

Trial Profile

Exploring the Impact of de Novo Everolimus on Key Determinants of Long Term Outcome After Kidney Transplantation: NODAT, Viral Infection, DSA, Proteinuria and Graft Histology

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolic acid; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms ADVISE
  • Sponsors Novartis
  • Most Recent Events

    • 14 Nov 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
    • 14 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
    • 06 Jan 2016 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top